Takeda ties up with startup on cancer immunotherapy 

September 4, 2017

TOKYO- Takeda Pharmaceutical Co. said Monday it has entered into a collaboration with Tokyo-based startup Noile-Immune Biotech Inc. on research and development for cancer immunotherapy.

Noile-Immune Biotech was launched in 2015 by the National Cancer Center Japan and Yamaguchi University.

The tie-up will include a next-generation therapy involving chimeric antigen receptor T cells, or CAR-T cells, which contain genes of antibodies that could recognize cancer and genes that stimulate activity in cells that attack tumor cells. Jiji Press